CT-based pancreatic radiomics predicts secondary loss of response to infliximab in biologically naïve patients with Crohn’s disease
Abstract Objectives Predicting secondary loss of response (SLR) to infliximab (IFX) is paramount for tailoring personalized management regimens. Concurrent pancreatic manifestations in patients with Crohn’s disease (CD) may correlate with SLR to anti-tumor necrosis factor treatment. This work aimed...
Main Authors: | Tian Yang, Jing Feng, Ruchen Yao, Qi Feng, Jun Shen |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2024-03-01
|
Series: | Insights into Imaging |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13244-024-01637-4 |
Similar Items
-
CT-based radiomics signature of visceral adipose tissue and bowel lesions for identifying patients with Crohn’s disease resistant to infliximab
by: Yangdi Wang, et al.
Published: (2024-01-01) -
CT-based radiomics signature of visceral adipose tissue for prediction of disease progression in patients with Crohn's disease: a multicentre cohort studyResearch in context
by: Xuehua Li, et al.
Published: (2023-02-01) -
MRI-Based Radiomic Signature Identifying Secondary Loss of Response to Infliximab in Crohn's Disease
by: Jing Feng, et al.
Published: (2022-01-01) -
Development and validation of a clinical radiomics nomogram to predict secondary loss of response to infliximab in Crohn's disease patients
by: Chao Zhu, et al.
Published: (2023-04-01) -
Radiology plus ileocolonoscopy versus radiology alone in Crohn’s disease: prognosis prediction and mutual agreement
by: Hye Kyung Hyun, et al.
Published: (2022-05-01)